| Innovation is GenSci's fundamental strategy. GenSci's R&D input accounts for more than12% of the total sales, being in a
leading position at the pharmaceutical industry.
GenSci owns the most advanced biological pilot scale technology platform. The newly developed drugs are all first in China,
partly patented internationally. In the coming three years, GenSci is going to launch six new products, three of them are the
biosimilars, and others are primary new drugs (patented, first in the world).
Innovation and research enable GenSci to successfully develop products of high technology, effective treatment, high safety, multi-formulation and multi-strengths in the field of child growth hormone deficiencies, endocrinology, burns, surgery,
oncology and assistant reproduction.
Particularly, GenLei® Jintropin® is the first and only somatropin in the world to be approved for treatment on burns. GenLei®
Jintropin® AQ is the only approved product for the indication of AGHD. GenSci's core product for the treatment of burns
treatment, GenLei® Genfulin® (gel), is the first in the world.
R&D Milestone
|
Year |
Product Name |
Status |
|
1998 |
Somatropin (rDNA origin) for Injection, Jintropin® |
1st in China
|
|
1998 |
rhG-CSF |
The 3rd generation of rhG-CSF, national patent |
|
2001 |
rhGH new indication approval (treating burns) |
Sole in the world |
|
2005 |
Somatropin (rDNA origin) Injection, Jintropin® AQ |
1st in the Asia, 3rd in the world |
|
2007 |
PEG rhGH Injection |
1st in the world, national patent |
|
2008 |
Recombinant thymosin α1 |
1st in the world, national patent |
|
2008 |
rhGM-CSF Gel |
1st in the world, national patent |
R&D Plan
|
No. |
Therapeutic Area |
Expected Launching Time |
Status |
|
Gensci 003 |
Hepatitis, tumor |
2013 |
Patented, 1st in the world |
|
Gensci 006 |
Pediatric, gynaecologic |
2013 |
1st biosimilar |
|
Gensci 007 |
Endocrinolgoy |
2013 |
1st biosimilar |
|
Gensci 028 |
Tumor |
2020 |
1st in the world |
|
